Status:
COMPLETED
CYP2C19 Gene Alteration and Thienopyridine Resistance in Percutaneous Coronary Intervention Study
Lead Sponsor:
Kumamoto University
Conditions:
Stable Angina
Eligibility:
All Genders
20+ years
Brief Summary
Dual antiplatelet therapy with aspirin and thienopyridines decreases the rate of stent thrombosis in patients undergoing percutaneous coronary intervention (PCI). However, despite intensified antiplat...
Detailed Description
We enrolled patients with stable effort angina who received dual-antiplatelet therapy with both aspirin (100mg) and clopidogrel (75mg). We performed PCI 12-24 hours after 300mg loading dose of clopido...
Eligibility Criteria
Inclusion
- The stable effort angina patients
- More than 20 years old
- Undergoing elective PCI treated with aspirin and clopidogrel
Exclusion
- Patients treated with the following medical therapy (ie. Warfarin, Steroid, thrombolytic drug, Ticlopidine, Sarpogrelate hydrochloride or Cilostazol)
- Patients with the following diseases (deep vein thrombosis, atrial fibrillation, collagen disease, infection, liver or renal dysfunction, malignant diseases)
Key Trial Info
Start Date :
December 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 1 2010
Estimated Enrollment :
104 Patients enrolled
Trial Details
Trial ID
NCT00876512
Start Date
December 1 2008
End Date
September 1 2010
Last Update
September 10 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kumamoto University Hospital
Kumamoto, Kumamoto, Japan, 860-8556